Holen Sie sich die Stockscreener-App
1.29
6.61%
0.08
Handel nachbörslich:
1.32
0.03
+2.33%
Schlusskurs vom Vortag:
$1.21
Offen:
$1.22
24-Stunden-Volumen:
1.37M
Relative Volume:
1.20
Marktkapitalisierung:
$150.39M
Einnahmen:
$4.35M
Nettoeinkommen (Verlust:
$-45.53M
KGV:
-1.1944
EPS:
-1.08
Netto-Cashflow:
$-44.79M
1W Leistung:
-7.19%
1M Leistung:
+4.88%
6M Leistung:
+53.55%
1J Leistung:
+62.33%
1-Tages-Spanne:
$1.21
$1.30
1-Wochen-Bereich:
$1.16
$1.36
52-Wochen-Spanne:
$0.681
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Firmenname
Lucid Diagnostics Inc
Sektor
Branche
Telefon
212 949 4319
Adresse
360 MADISON AVENUE, NEW YORK
Vergleichen Sie LUCD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.29 | 150.39M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2021-11-08 | Eingeleitet | BTIG Research | Buy |
| 2021-11-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Needham | Buy |
Lucid Diagnostics Inc Aktie (LUCD) Neueste Nachrichten
Lucid Diagnostics (LUCD) Stock Maintained at Buy by Ascendiant Capital | LUCD Stock News - GuruFocus
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 - Investing.com India
Lucid Diagnostics (LUCD) Target Price Increased by Ascendiant | - GuruFocus
Lucid Diagnostics Files For Offering Of 36 Million Shares Of Common Stock - marketscreener.com
Pavmed's Veris Health Signs Long-Term Partnership Deal With Ohio State University Hospital - marketscreener.com
Lucid Diagnostics Enters $25M Sales Agreement - TipRanks
Lucid Diagnostics joins Russell 2000 and 3000 indexes - Mugglehead Magazine
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes - The Malaysian Reserve
Lucid Diagnostics to Join Russell 2000, Russell 3000 Indexes - marketscreener.com
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com South Africa
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes - Investing.com Australia
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Indexes | LUCD Stock News - GuruFocus
Lucid Diagnostics Joins Elite Russell Indexes, Opens Door to $10.6T Investment Pool - Stock Titan
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Ind - GuruFocus
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.50 Consensus Price Target from Brokerages - Defense World
Certain Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - marketscreener.com
Certain Common Stock of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - marketscreener.com
Insider Buying: Dennis Matheis Acquires 350,000 Shares of Lucid Diagnostics Inc (LUCD) - GuruFocus
Lucid Diagnostics (LUCD) Director Acquires Significant Shares | - GuruFocus
Lucid Diagnostics (LUCD) Director Acquires Significant Shares | LUCD Stock News - GuruFocus
Lucid Diagnostics Files Shelf Registration for Secondary Sale of 37 Million Shares by Convertible Note Holders - marketscreener.com
Lucid Diagnostics (LUCD) Files to Sell 36.98 Million Shares | LU - GuruFocus
Lucid Diagnostics Files Prospectus For Potential Offer, Sale From Time To Time Of Up To 37 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
Lucid Diagnostics (LUCD) Files to Sell 36.98 Million Shares | LUCD Stock News - GuruFocus
Lucid Diagnostics’ SWOT analysis: stock faces reimbursement hurdles amid market potential - Investing.com Nigeria
Cantor Fitzgerald maintains Lucid Diagnostics stock Overweight - Investing.com Australia
Cantor Fitzgerald maintains Lucid Diagnostics stock Overweight By Investing.com - Investing.com India
Lucid Diagnostics’ (LUCD) Buy Rating Reiterated at Needham & Company LLC - Defense World
Cantor Fitzgerald Reiterates “Overweight” Rating for Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Lucid Diagnostics (LUCD) Stock Rating Reiterated by Cantor Fitzg - GuruFocus
Lucid Diagnostics signals expanded market reach and $41M pro forma cash following commercial and clinical advances - MSN
Lucid Diagnostics Reports Increased Losses Amid Revenue Decline - TipRanks
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates - MSN
Cantor maintains Lucid Diagnostics stock with $2 target after Q1 results - Investing.com Australia
Lucid Diagnostics (LUCD) Stock Rating Reiterated by Cantor Fitzgerald | LUCD Stock News - GuruFocus
Transcript : PAVmed Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
PAVmed Inc Q1 2025 Earnings: Revenue Surges to $0.8 Million, Bea - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 F - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results | PAVM Stock News - GuruFocus
PAVmed Q1 Earnings: $40M Cash Runway Powers Multi-Subsidiary Growth and Biopharma Entry Plans - Stock Titan
PAVmed Inc. SEC 10-Q Report - TradingView
Cantor maintains Lucid Diagnostics stock with $2 target after Q1 results By Investing.com - Investing.com South Africa
Lucid Diagnostics Q1 2025 Earnings Call Transcript - MarketBeat
Lucid Diagnostics (LUCD) Sees Strong Q1 Performance with Expanded Testing - GuruFocus
Earnings call transcript: Lucid Diagnostics Q1 2025 highlights growth and strategic expansion - Investing.com Nigeria
Lucid Diagnostics (LUCD) Stock: Needham Reiterates Buy Rating | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Misses Q1 Revenue Estimates, Focuses on Growth | LUCD Stock News - GuruFocus
Transcript : Lucid Diagnostics Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Finanzdaten der Lucid Diagnostics Inc-Aktie (LUCD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.56%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):